MedTrace Logo

Allogeneic Multipotent Stromal Cell Treatment for Acute Kidney Injury Following Cardiac Surgery

NCT00733876 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2014-08-06

No results posted yet for this study

Summary

The purpose of this trial is to determine if the administration of allogeneic MSCs at defined doses is safe in patients who are at high risk of developing significant Acute Kidney Injury (AKI) after undergoing on-pump cardiac surgery.

Conditions

  • Kidney Tubular Necrosis, Acute

Interventions

BIOLOGICAL

Multipotent Stromal Cells

Post-operative administration of MSC

BIOLOGICAL

Administration of MSC

Dose escalation protocol

Sponsors & Collaborators

  • Intermountain Health Care, Inc.

    collaborator OTHER

  • St Mark's Hospital Foundation

    collaborator OTHER

  • AlloCure Inc.

    lead INDUSTRY

Principal Investigators

  • Christof Westenfelder, MD · AlloCure Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2010-05-31
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00733876 on ClinicalTrials.gov